Frankfurt
09.11.26 | 09:08
5,100 Euro
0,00 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 4,600 | 4,740 | 18:12 | |
| 4,600 | 4,740 | 18:13 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15:18 | Exagen Q3 2026 Earnings Call Transcript | 1 | Benzinga.com | ||
| 14:30 | Exagen GAAP EPS of -$0.25 misses by $0.07, revenue of $18.42M beats by $0.08M | 1 | Seeking Alpha | ||
| 14:01 | EXAGEN INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 13:50 | Exagen Inc Q3 Loss Drops | 1 | RTTNews | ||
| 13:48 | Exagen Inc. Reports Third Quarter 2026 Financial Results | 1 | GlobeNewswire (USA) | ||
| EXAGEN Aktie jetzt für 0€ handeln | |||||
| 12:33 | EXAGEN INC. - 8-K, Current Report | - | SEC Filings | ||
| Mo | Exagen Q3 2026 Earnings Preview | 3 | Seeking Alpha | ||
| 27.10. | Exagen Inc.: Exagen to Announce Third Quarter Financial Results on November 10, 2026 | 1 | GlobeNewswire (USA) | ||
| 17.09. | Full Transcript: Exagen Q2 2026 Earnings Call | 2 | Benzinga.com | ||
| 11.08. | Exagen auf Wachstumskonferenz von Canaccord Genuity: Turnaround gewinnt an Fahrt | 5 | Investing.com Deutsch | ||
| 04.08. | Exagen targets $72M-$75M 2026 revenue outlook as profitability nears breakeven | 4 | Seeking Alpha | ||
| 04.08. | Exagen Q2 2026 slides: record revenue, stock surges 30% on results | 2 | Investing.com | ||
| 04.08. | Exagen Q2 2026 slides: record revenue, stock surges 36% | 2 | Investing.com | ||
| 04.08. | EXAGEN INC. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 04.08. | Exagen GAAP EPS of -$0.13 beats by $0.06, revenue of $19.94M beats by $2.07M | 2 | Seeking Alpha | ||
| 04.08. | Exagen Inc. Reports Second Quarter 2026 Financial Results | 660 | GlobeNewswire (Europe) | Achieved record total revenue, test volume and trailing twelve-month ASP Reduced net loss by nearly 30% and narrowed adjusted EBITDA loss to $0.1 million Increased full-year revenue guidance to... ► Artikel lesen | |
| 04.08. | EXAGEN INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 21.07. | Exagen Inc.: Exagen to Announce Second Quarter Financial Results on August 4, 2026 | 1 | GlobeNewswire (USA) | ||
| 09.06. | EXAGEN INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.06. | Exagen Inc.: Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus | 1 | GlobeNewswire (USA) |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 7,782 | -2,70 % | Teladoc Health, Inc.: Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08 | ||
| HIMS & HERS HEALTH | 16,910 | -17,35 % | Neuer Vertriebskanal: Der nächste Coup im Abnehm-Markt? Eli Lilly überrascht mit diesem Deal | © Foto: Sascha Lotz/dpaEli Lilly geht eine ungewöhnliche Partnerschaft ein. Das steckt hinter dem neuen Vertriebsweg für seine Abnehmmedikamente Enthaltene Werte: US5324571083,US4330001060Den vollständigen... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,067 | -1,19 % | Sernova Biotherapeutics, Inc.: Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial | TORONTO and GERMANTOWN, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO) and Seraxis Holdings, Inc. ("Seraxis") today announced... ► Artikel lesen | |
| CERENOME | 0,580 | +10,27 % | Cerenome names Ron Andrews as chief business officer | ||
| ATOSSA THERAPEUTICS | 1,930 | +1,05 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update | SEATTLE, Nov. 10, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other... ► Artikel lesen | |
| HENRY SCHEIN | 77,00 | -2,53 % | Henry Schein, Inc.: Henry Schein to Participate in Upcoming Investor Conferences in November and December | Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that the Company will present at the following... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -5- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS75973T2006 RENALYTIX... ► Artikel lesen | |
| TANDEM DIABETES | 14,900 | -8,02 % | Tandem Diabetes Care names successor as CEO Sheridan retires | ||
| CO-DIAGNOSTICS | 0,282 | -11,76 % | Co-Diagnostics Reports Third Quarter 2026 Financial Results | Two Regulatory Submissions Under Review in India and the U.S. Third Quarter Operating Expenses Down 12% Year Over YearPlatform Capabilities Expanding with ReadyGo Collaboration, India Connectivity and... ► Artikel lesen | |
| QUIDELORTHO | 10,730 | -0,42 % | QuidelOrtho expects over $80M in 2027 annual savings as it narrows 2026 revenue to $2.52B-$2.54B | ||
| AMBU | 11,740 | +0,43 % | Ambu A/S: Interim Report For Q4 2025/26 And Outlook For Fy 2026/27 | 5.11.2026 07:00:06 CET | Ambu A/S |
Annual Financial Report
Strong organic revenue growth in Q4 of 13.9% and an EBIT margin of 17.2% resulted in Ambu closing the financial year within the guidance... ► Artikel lesen | |
| VERU | 2,150 | -1,83 % | Veru executive to present obesity drug data at industry conference | ||
| LIFEWARD | 6,050 | +1,85 % | Lifeward Ltd. - 8-K, Current Report | ||
| CLOVER HEALTH INVESTMENTS | 4,320 | +0,23 % | Clover Health auf der UBS Global Healthcare Conference: Starkes Wachstum trifft auf steigende Ertragskraft | ||
| SENSEONICS | 11,400 | +30,29 % | Senseonics delivers 'breakout quarter' more than doubling Eversense 365 revenue |
EXAGEN INC gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 5,100 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EXAGEN INC finden Sie auf Wallstreet Online.